Turing Pharmaceuticals, which is developing intranasal oxytocin and ketamine products, has announced that it has hired Eliseo Oreste Salinas as President of Research and Development. Salinas was most recently President and Chief Scientific Officer of Relmada Therapeutics.
According to the company, “He arrives as Turing prepares to begin clinical trials for several of its drugs, including an innovative intranasal formulation for ketamine to treat severe depression and suicidality.”
Turing Founder and Chairman Martin Shkreli commented, “We are pleased to welcome Eliseo Salinas to our leadership team. Eliseo combines proven capabilities to bring important new treatments to patients and their physicians, with a deep understanding of the patient and physician communities. His appointment is another major step as we build Turing’s capabilities for the long-term, advance our existing pipeline and work to create and acquire new assets.”
Salinas said, “I am excited to be joining Turing. It is a special opportunity to be part of a dynamic young company with an important portfolio of assets in development, a strong management team and a great vision. I look forward to helping to accelerate Turing’s success and contribution to healthcare.”
In October 2014, Retrophin announced that Shkreli had agreed to resign from Retrophin and that his new company, Turing, would pay $3 million up front for several Retrophin products, including Syntocinon. Turing officially announced its launch in February 2015.
Read the Turing press release.
